Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Guichard S, Hennebelle I, Bugat R, Canal P. Guichard S, et al. Among authors: hennebelle i. Biochem Pharmacol. 1998 Mar 1;55(5):667-76. doi: 10.1016/s0006-2952(97)00541-8. Biochem Pharmacol. 1998. PMID: 9515577
CPT-11 (irinotecan) is a DNA topoisomerase I inhibitor active against metastatic colorectal carcinoma. We investigated, in a human colon carcinoma cell line, HT-29, the effects of CPT-11 and 5-fluorouracil (5FU) combinations. ...
CPT-11 (irinotecan) is a DNA topoisomerase I inhibitor active against metastatic colorectal carcinoma. We investigated, in a human co …
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord JP, Toulas C, Chatelut E. Thomas F, et al. Among authors: hennebelle i. Clin Pharmacol Ther. 2016 Feb;99(2):235-42. doi: 10.1002/cpt.210. Epub 2015 Nov 10. Clin Pharmacol Ther. 2016. PMID: 26265035
Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, Chatelut E, Thomas F. Sauzay C, et al. Among authors: hennebelle i. Pharmacol Res. 2016 Aug;110:89-95. doi: 10.1016/j.phrs.2016.05.012. Epub 2016 May 10. Pharmacol Res. 2016. PMID: 27178732
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.
Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Arnould S, et al. Among authors: hennebelle i. Eur J Cancer. 2003 Jan;39(1):112-9. doi: 10.1016/s0959-8049(02)00411-2. Eur J Cancer. 2003. PMID: 12504667
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma.
Delord JP, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, Pradines A, Chatelut E, Bugat R, Guichard S, Canal P. Delord JP, et al. Among authors: hennebelle i. Ann Oncol. 2005 Dec;16(12):1889-97. doi: 10.1093/annonc/mdi405. Epub 2005 Oct 11. Ann Oncol. 2005. PMID: 16219625
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Guichard S, Montazeri A, Chatelut E, Hennebelle I, Bugat R, Canal P. Guichard S, et al. Among authors: hennebelle i. Clin Cancer Res. 2001 Oct;7(10):3222-8. Clin Cancer Res. 2001. PMID: 11595718
Topotecan is a topoisomerase (Topo) I inhibitor used in ovarian carcinoma chemotherapy. Topo I inhibitors are thought to be more cytotoxic using protracted schedules of administration. We tested this hypothesis on a preclinical model: human ovarian carcinoma OVCAR-3 …
Topotecan is a topoisomerase (Topo) I inhibitor used in ovarian carcinoma chemotherapy. Topo I inhibitors are thought to be mo …
Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P. Guichard S, et al. Among authors: hennebelle i. Anticancer Drugs. 2001 Oct;12(9):741-51. doi: 10.1097/00001813-200110000-00006. Anticancer Drugs. 2001. PMID: 11593056
The persistence of platinum-DNA adducts in the presence of irinotecan could be due to a direct impact of irinotecan on NER gene expression or to an indirect effect on topoisomerase I activity. ...
The persistence of platinum-DNA adducts in the presence of irinotecan could be due to a direct impact of irinotecan on NER gene expression o …
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Hennebelle I, Terret C, Chatelut E, Bugat R, Canal P, Guichard S. Hennebelle I, et al. Anticancer Drugs. 2000 Jul;11(6):465-70. doi: 10.1097/00001813-200007000-00007. Anticancer Drugs. 2000. PMID: 11001387
Irinotecan (CPT-11) is a topoisomerase I inhibitor commonly used in the treatment of colorectal tumors. It is a prodrug, converted to an active metabolite, SN-38, by carboxylesterases (CEs). ...
Irinotecan (CPT-11) is a topoisomerase I inhibitor commonly used in the treatment of colorectal tumors. It is a prodrug, converted to …
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Frétigny E, Selves J, Chatelut E, Bugat R, Canal P. Guichard S, et al. Among authors: hennebelle i. Br J Cancer. 1999 May;80(3-4):364-70. doi: 10.1038/sj.bjc.6690364. Br J Cancer. 1999. PMID: 10408839 Free PMC article.
CPT-11 is a prodrug activated by carboxylesterases to the active metabolite SN-38 which is a potent inhibitor of topoisomerase I. ...We evaluated the activities of CPT-11 converting carboxylesterase (CPT-CE) and topoisomerase I (topo I) in 53 colorectal tumou …
CPT-11 is a prodrug activated by carboxylesterases to the active metabolite SN-38 which is a potent inhibitor of topoisomerase I. ... …
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P. Guichard S, et al. Among authors: hennebelle i. Int J Cancer. 1997 Nov 27;73(5):729-34. doi: 10.1002/(sici)1097-0215(19971127)73:5<729::aid-ijc20>3.0.co;2-#. Int J Cancer. 1997. PMID: 9398054
Irinotecan, a DNA-topoisomerase-I inhibitor, is active against metastatic colon carcinoma. We investigated the effects of irinotecan and 5FU combinations in human colon-carcinoma cell line HT-29, both in vitro and in vivo. ...In nude-mice xenografts, schedule-dependent tox …
Irinotecan, a DNA-topoisomerase-I inhibitor, is active against metastatic colon carcinoma. We investigated the effects of irinotecan …
25 results
Jump to page
Feedback